Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
Eligible subjects must have a primary diagnosis of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1:1 ratio to be treated with solriamfetol 150 mg, solriamfetol 300 mg, or placebo, once daily for 6 weeks.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary diagnosis of ADHD according to DSM-5 criteria.
Provides written informed consent to participate in the study before the conduct of any study procedures.
Male or female, aged 18 to 55 inclusive.
You may not be if
Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
Unable to comply with study procedures.
Medically inappropriate for study participation in the opinion of the investigator.
Clareo Health | A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
